The multiple PDZ domain protein Mpdz/MUPP1 regulates opioid tolerance and opioid-induced hyperalgesia

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Donaldson, Robin ^a   Sun, Yuan ^b,c   Liang, De Yong ^b,c   Zheng, Ming ^c   Sahbaie, Peyman ^b,c   Dill, David L ^a   Peltz, Gary ^c   Buck, Kari J ^d   Clark, J David ^b,c  

^a Stanford University   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Drug tolerance; Gene mapping; Opioid analgesics; Synaptic plasticity

Indexed keywords

MORPHINE SULFATE; PDZ PROTEIN; CARRIER PROTEIN; MORPHINE; MPDZ PROTEIN, MOUSE; NARCOTIC ANALGESIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; GENE EXPRESSION; GENE FUNCTION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; HAPLOTYPE; HETEROZYGOTE; HYPERALGESIA; IMMUNOPRECIPITATION; LATENT PERIOD; MALE; MOUSE; MPDZ GENE; NERVE CELL PLASTICITY; NONHUMAN; OPIOID INDUCED HYPERALGESIA; REGULATOR GENE; ANIMAL; CHEMICALLY INDUCED; CHROMOSOMAL MAPPING; DOSE RESPONSE; GENE SILENCING; GENETICS; INBRED MOUSE STRAIN; MORPHINE ADDICTION; PDZ DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

ANALGESICS, OPIOID; ANIMALS; CARRIER PROTEINS; CHROMOSOME MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GENE KNOCKDOWN TECHNIQUES; HAPLOTYPES; HYPERALGESIA; MALE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MORPHINE; MORPHINE DEPENDENCE; PDZ DOMAINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84966330270     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-016-2634-1     Document Type: Article

References (57)

1. Centers for Disease C, Prevention. CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10-3.
2. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med. 2012;6(2):e41-47.
3. Fredheim OM, Borchgrevink PC, Mahic M, Skurtveit S. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: a study from the Norwegian Prescription Database. Pain. 2013;154(11):2487-93.
4. Mekhail N, Mahboobi R, Farajzadeh Deroee A, Costandi S, Dalton J, Guirguis M, Mehta P. Factors that might impact intrathecal drug delivery (IDD) dose escalation: a longitudinal study. Pain Pract. 2014;14(4):301-8.
5. Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, Brummett C, Mao J. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med. 2008;33(3):199-206.
6. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686-91.
7. Bekhit MH. Opioid-induced hyperalgesia and tolerance. Am J Ther. 2010;17(5):498-510.
8. Kest B, Palmese CA, Hopkins E, Adler M, Juni A, Mogil JS. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience. 2002;115(2):463-9.
9. Liang DY, Liao G, Lighthall GK, Peltz G, Clark DJ. Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogenet Genomics. 2006;16(11):825-35.
10. Liang DY, Guo T, Liao G, Kingery WS, Peltz G, Clark JD. Chronic pain and genetic background interact and influence opioid analgesia, tolerance, and physical dependence. Pain. 2006;121(3):232-40.
11. Wilson SG, Smith SB, Chesler EJ, Melton KA, Haas JJ, Mitton B, Strasburg K, Hubert L, Rodriguez-Zas SL, Mogil JS. The heritability of antinociception: common pharmacogenetic mediation of five neurochemically distinct analgesics. J Pharmacol Exp Ther. 2003;304(2):547-59.
12. Tapocik JD, Letwin N, Mayo CL, Frank B, Luu T, Achinike O, House C, Williams R, Elmer GI, Lee NH. Identification of candidate genes and gene networks specifically associated with analgesic tolerance to morphine. J Neurosci. 2009;29(16):5295-307.
13. Chu LF, Liang DY, Li X, Sahbaie P, D'Arcy N, Liao G, Peltz G, David Clark J. From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics. Pharmacogenet Genomics. 2009;19(3):193-205.
14. Kest B, Smith SB, Schorscher-Petcu A, Austin JS, Ritchie J, Klein G, Rossi GC, Fortin A, Mogil JS. Gnao1 (G alphaO protein) is a likely genetic contributor to variation in physical dependence on opioids in mice. Neuroscience. 2009;162(4):1255-64.
15. Liang DY, Shi X, Li X, Li J, Clark JD. The beta2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav Brain Res. 2007;181(1):118-26.
16. Chu LF, Cun T, Ngai LK, Kim JE, Zamora AK, Young CA, Angst MS, Clark DJ. Modulation of remifentanil-induced postinfusion hyperalgesia by the beta-blocker propranolol in humans. Pain. 2012;153(5):974-81.
17. Zheng M, Zhang H, Dill DL, Clark JD, Tu S, Yablonovitch AL, Tan MH, Zhang R, Rujescu D, Wu M, et al. The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans. PLoS Med. 2015;12(2):e1001782.
18. Liang DY, Zheng M, Sun Y, Sahbaie P, Low SA, Peltz G, Scherrer G, Flores C, Clark JD. The Netrin-1 receptor DCC is a regulator of maladaptive responses to chronic morphine administration. BMC Genomics. 2014;15:345.
19. Glickman ME, Rao SR, Schultz MR. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol. 2014;67(8):850-7.
20. Berta T, Liu YC, Xu ZZ, Ji RR. Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1beta and ERK signaling in the spinal cord of mice. Neuroscience. 2013;247:376-85.
21. Rygh LJ, Green M, Athauda N, Tjolsen A, Dickenson AH. Effect of spinal morphine after long-term potentiation of wide dynamic range neurones in the rat. Anesthesiology. 2000;92(1):140-6.
22. Ackermann F, Zitranski N, Borth H, Buech T, Gudermann T, Boekhoff I. CaMKIIalpha interacts with multi-PDZ domain protein MUPP1 in spermatozoa and prevents spontaneous acrosomal exocytosis. J Cell Sci. 2009;122(Pt 24):4547-57.
23. Chen Y, Yang C, Wang ZJ. Ca2+/calmodulin-dependent protein kinase II alpha is required for the initiation and maintenance of opioid-induced hyperalgesia. J Neurosci. 2010;30(1):38-46.
24. Liang D, Li X, Clark JD. Increased expression of Ca2+/calmodulin-dependent protein kinase II alpha during chronic morphine exposure. Neuroscience. 2004;123(3):769-75.
25. Wang ZJ, Tang L, Xin L. Reversal of morphine antinociceptive tolerance by acute spinal inhibition of Ca(2+)/calmodulin-dependent protein kinase II. Eur J Pharmacol. 2003;465(1-2):199-200.
26. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570-87.
27. Milner LC, Shirley RL, Kozell LB, Walter NA, Kruse LC, Komiyama NH, et al. Novel MPDZ/MUPP1 transgenic and knockdown models confirm Mpdz's role in ethanol withdrawal and support its role in voluntary ethanol consumption. Addict Biol. 2013;20(1):143-7.
28. Krapivinsky G, Medina I, Krapivinsky L, Gapon S, Clapham DE. SynGAP-MUPP1-CaMKII synaptic complexes regulate p38 MAP kinase activity and NMDA receptor-dependent synaptic AMPA receptor potentiation. Neuron. 2004;43(4):563-74.
29. Inturrisi CE. The role of N-methyl-D-aspartate (NMDA) receptors in pain and morphine tolerance. Minerva Anestesiol. 2005;71(7-8):401-3.
30. Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res. 2001;86(1-2):56-62.
31. Sahbaie P, Shi X, Li X, Liang D, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, David Clark J. Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice. J Pain. 2012;13(10):997-1007.
32. Ullmer C, Schmuck K, Figge A, Lubbert H. Cloning and characterization of MUPP1, a novel PDZ domain protein. FEBS Lett. 1998;424(1-2):63-8.
33. Simpson EH, Suffolk R, Jackson IJ. Identification, sequence, and mapping of the mouse multiple PDZ domain protein gene, Mpdz. Genomics. 1999;59(1):102-4.
34. Khan Z, Lafon M. PDZ domain-mediated protein interactions: therapeutic targets in neurological disorders. Curr Med Chem. 2014;21(23):2632-41.
35. Hamazaki Y, Itoh M, Sasaki H, Furuse M, Tsukita S. Multi-PDZ domain protein 1 (MUPP1) is concentrated at tight junctions through its possible interaction with claudin-1 and junctional adhesion molecule. J Biol Chem. 2002;277(1):455-61.
36. Jeansonne B, Lu Q, Goodenough DA, Chen YH. Claudin-8 interacts with multi-PDZ domain protein 1 (MUPP1) and reduces paracellular conductance in epithelial cells. Cell Mol Biol. 2003;49(1):13-21.
37. Liew CW, Vockel M, Glassmeier G, Brandner JM, Fernandez-Ballester GJ, Schwarz JR, Schulz S, Buck F, Serrano L, Richter D, et al. Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Lett. 2009;583(1):49-54.
38. Sindic A, Huang C, Chen AP, Ding Y, Miller-Little WA, Che D, Romero MF, Miller RT. MUPP1 complexes renal K+ channels to alter cell surface expression and whole cell currents. Am J Physiol Renal Physiol. 2009;297(1):F36-45.
39. Sitek B, Poschmann G, Schmidtke K, Ullmer C, Maskri L, Andriske M, Stichel CC, Zhu XR, Luebbert H. Expression of MUPP1 protein in mouse brain. Brain Res. 2003;970(1-2):178-87.
40. Befort K, Filliol D, Ghate A, Darcq E, Matifas A, Muller J, Lardenois A, Thibault C, Dembele D, Le Merrer J, et al. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Eur J Neurosci. 2008;27(11):2973-84.
41. Nassirpour R, Bahima L, Lalive AL, Luscher C, Lujan R, Slesinger PA. Morphine- and CaMKII-dependent enhancement of GIRK channel signaling in hippocampal neurons. J Neurosci. 2010;30(40):13419-30.
42. Fujita E, Tanabe Y, Imhof BA, Momoi MY, Momoi T. A complex of synaptic adhesion molecule CADM1, a molecule related to autism spectrum disorder, with MUPP1 in the cerebellum. J Neurochem. 2012;123(5):886-94.
43. Li X, Lynn BD, Nagy JI. The effector and scaffolding proteins AF6 and MUPP1 interact with connexin36 and localize at gap junctions that form electrical synapses in rodent brain. Eur J Neurosci. 2012;35(2):166-81.
44. Estevez MA, Henderson JA, Ahn D, Zhu XR, Poschmann G, Lubbert H, Marx R, Baraban JM. The neuronal RhoA GEF, Tech, interacts with the synaptic multi-PDZ-domain-containing protein, MUPP1. J Neurochem. 2008;106(3):1287-97.
45. Balasubramanian S, Fam SR, Hall RA. GABAB receptor association with the PDZ scaffold Mupp1 alters receptor stability and function. J Biol Chem. 2007;282(6):4162-71.
46. Rama S, Krapivinsky G, Clapham DE, Medina I. The MUPP1-SynGAPalpha protein complex does not mediate activity-induced LTP. Mol Cell Neurosci. 2008;38(2):183-8.
47. Miyamoto Y, Yamada K, Nagai T, Mori H, Mishina M, Furukawa H, Noda Y, Nabeshima T. Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit. Eur J Neurosci. 2004;19(1):151-8.
48. Ko SW, Wu LJ, Shum F, Quan J, Zhuo M. Cingulate NMDA NR2B receptors contribute to morphine-induced analgesic tolerance. Mol Brain. 2008;1:2.
49. Liaw WJ, Zhu XG, Yaster M, Johns RA, Gauda EB, Tao YX. Distinct expression of synaptic NR2A and NR2B in the central nervous system and impaired morphine tolerance and physical dependence in mice deficient in postsynaptic density-93 protein. Mol Pain. 2008;4:45.
50. Kest B, McLemore G, Kao B, Inturrisi CE. The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids. J Pharmacol Exp Ther. 1997;283(3):1249-55.
51. McLemore GL, Kest B, Inturrisi CE. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. Brain Res. 1997;778(1):120-6.
52. Buck KJ, Milner LC, Denmark DL, Grant SG, Kozell LB. Discovering genes involved in alcohol dependence and other alcohol responses: role of animal models. Alcohol Res. 2012;34(3):367-74.
53. Ehlers CL, Walter NA, Dick DM, Buck KJ, Crabbe JC. A comparison of selected quantitative trait loci associated with alcohol use phenotypes in humans and mouse models. Addict Biol. 2010;15(2):185-99.
54. Karpyak VM, Kim JH, Biernacka JM, Wieben ED, Mrazek DA, Black JL, Choi DS. Sequence variations of the human MPDZ gene and association with alcoholism in subjects with European ancestry. Alcohol Clin Exp Res. 2009;33(4):712-21.
55. Shirley RL, Walter NA, Reilly MT, Fehr C, Buck KJ. Mpdz is a quantitative trait gene for drug withdrawal seizures. Nat Neurosci. 2004;7(7):699-700.
56. Peltz G, Zaas AK, Zheng M, Solis NV, Zhang MX, Liu HH, Hu Y, Boxx GM, Phan QT, Dill D, et al. Next-generation computational genetic analysis: multiple complement alleles control survival after Candida albicans infection. Infect Immun. 2011;79(11):4472-9.
57. Liang DY, Liao G, Wang J, Usuka J, Guo Y, Peltz G, Clark JD. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology. 2006;104(5):1054-62.